Next Article in Journal
Checkpoint Inhibition: Will Combination with Radiotherapy and Nanoparticle-Mediated Delivery Improve Efficacy?
Previous Article in Journal
Antioxidant, Antifungal, Antibiofilm, and Cytotoxic Activities of Mentha spp. Essential Oils
Open AccessCase Report

Severe Brief Resolved Unexplained Event in a Newborn Infant in Association with Maternal Sertralin Treatment during Pregnancy

Division of Neonatology, Department of Pediatrics, Medical University of Graz, 8036 Graz, Austria
*
Author to whom correspondence should be addressed.
Medicines 2018, 5(4), 113; https://doi.org/10.3390/medicines5040113
Received: 30 June 2018 / Revised: 13 October 2018 / Accepted: 17 October 2018 / Published: 22 October 2018
  |  
PDF [219 KB, uploaded 22 October 2018]

Abstract

Background: Selective serotonin reuptake inhibitors are a very common choice of antidepressive drug-therapy during pregnancy. In up to 30% of cases, they have been found to cause neonatal abstinence syndrome in newborn infants. Although often both time-limiting and self-limiting, severe symptoms of neonatal abstinence syndrome (NAS) can occur. Methods/Results: We report a term male infant suffering from a severe brief resolved unexplained event caused by his mother’s sertraline intake during pregnancy. Conclusions: Newborn infants exposed to selective serotonine reuptake inhibitors (SSRIs) during pregnancy should be evaluated very carefully concerning NAS and monitored for NAS symptoms for a minimum of 72–96 h, or until symptoms have fully recovered using standardized protocols. There is a risk of severe NAS symptoms which might occur, and this circumstance should be discussed with the parents and taken into account before administering the drug. View Full-Text
Keywords: neonatal abstinence syndrome; selective serotonine reuptake inhibitor; brief resolved unexplained events; apparent life-threatening events neonatal abstinence syndrome; selective serotonine reuptake inhibitor; brief resolved unexplained events; apparent life-threatening events
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Pocivalnik, M.; Danda, M.; Urlesberger, B.; Raith, W. Severe Brief Resolved Unexplained Event in a Newborn Infant in Association with Maternal Sertralin Treatment during Pregnancy. Medicines 2018, 5, 113.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Medicines EISSN 2305-6320 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top